M-ACT
Symptomatic cartilage defects of the knee joint
ApprovedActive
Key Facts
About CO.DON
CO.DON is a clinical-stage biotech company developing autologous cell therapies for cartilage repair, aiming to delay or avoid joint replacement surgery. The company's lead product, M-ACT (Matrix-associated Autologous Chondrocyte Transplantation), is an approved therapy in the EU. Following its 2023 acquisition by the global regenerative medicine group ReLive Biotechnology, CO.DON is positioned to expand its commercial footprint and pipeline under new leadership. The company targets the significant unmet medical need in orthopedics caused by degenerative joint diseases and sports injuries.
View full company profile